- Current status
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
Monthly Archives: June 2014
What it takes to be the best. http://www.newyorker.com/archive/2004/12/06/041206fa_fact?printable=true¤tPage=all I am slowly strating to think about the Boston trip. Whom should I meet there. I am looking forward to meeting Atul Gawande.
Very interesting data coming from the studies in breast cancer. Patients receiving Zoladex with chemotherapy are more likely to have menstruation after chemotherapy and also more likely to have children after the treatment. http://www.medpagetoday.com/HematologyOncology/BreastCancer/46073 http://www.doz.pl/leki/p2900-Zoladex